Illumina, Inc. Stock price

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
137.3 USD -0.98% Intraday chart for Illumina, Inc. -0.09% -1.38%
Sales 2024 * 4.52B Sales 2025 * 4.99B Capitalization 21.82B
Net income 2024 * -115M Net income 2025 * 253M EV / Sales 2024 * 4.84 x
Net Debt 2024 * 23.7M Net cash position 2025 * 844M EV / Sales 2025 * 4.21 x
P/E ratio 2024 *
-245 x
P/E ratio 2025 *
73.1 x
Employees 10,615
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.98%
1 week-0.09%
Current month-1.80%
1 month-2.60%
3 months-3.38%
6 months+3.76%
Current year-1.38%
More quotes
1 week
132.77
Extreme 132.77
140.07
1 month
125.82
Extreme 125.82
144.19
Current year
125.82
Extreme 125.82
148.19
1 year
89.00
Extreme 89
233.42
3 years
89.00
Extreme 89
526.00
5 years
89.00
Extreme 89
555.77
10 years
89.00
Extreme 89
555.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 23-09-24
Director of Finance/CFO 52 19-09-22
Chief Tech/Sci/R&D Officer - 97-12-31
Members of the board TitleAgeSince
Director/Board Member 69 12-11-28
Chairman 60 23-06-01
Director/Board Member 64 17-01-26
More insiders
Date Price Change Volume
24-03-28 137.3 -0.98% 917,083
24-03-27 138.7 +3.65% 951,642
24-03-26 133.8 -0.19% 1,126,971
24-03-25 134.1 -2.32% 966,983
24-03-22 137.2 -0.15% 1,295,148

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
137.3 USD
Average target price
160 USD
Spread / Average Target
+16.52%
Consensus
  1. Stock
  2. Equities
  3. Stock Illumina, Inc. - Nasdaq